HALO:NGS-Halozyme Therapeutics Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 49.5

Change

0.00 (0.00)%

Market Cap

USD 1.64B

Volume

1.42M

Analyst Target

USD 33.20
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Halozyme Therapeutics Inc is a biopharmaceutical company. It is engaged in research on human enzymes that alter the extracellular matrix and tumor environment.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-15 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 122.24B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 115.08B
MRNA Moderna Inc

N/A

USD 51.07B
ARGX argenx NV ADR

N/A

USD 23.44B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 20.96B
BNTX BioNTech SE

N/A

USD 20.40B
BGNE BeiGene Ltd

N/A

USD 17.50B
GMAB Genmab AS

N/A

USD 16.65B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 15.98B
RPRX Royalty Pharma Plc

N/A

USD 15.90B

ETFs Containing HALO

FBT:LSE First Trust Global Funds .. 4.25 % 0.00 %

N/A

USD 5.63M
FBTU:LSE First Trust Global Funds .. 4.25 % 0.00 %

N/A

USD 5.63M
FBT First Trust NYSE Arca Bio.. 4.11 % 0.57 %

N/A

USD 1.12B
FFND The Future Fund Active ET.. 3.85 % 0.00 %

N/A

USD 0.01B
BIGT:LSE L&G Pharma Breakthrough U.. 2.97 % 0.00 %

N/A

USD 0.02B
ETLI:F Legal & General UCITS ETF.. 2.60 % 0.00 %

N/A

USD 0.02B
ETLI:XETRA L&G Pharma Breakthrough U.. 2.60 % 0.00 %

N/A

USD 0.02B
BIOT:SW L&G Pharma Breakthrough U.. 2.60 % 0.00 %

N/A

N/A
BBP Virtus LifeSci Biotech Pr.. 2.42 % 0.79 %

N/A

USD 0.02B
XBI SPDR® S&P Biotech ETF 1.33 % 0.35 %

N/A

USD 7.07B
SMDY Syntax ETF Trust - Syntax.. 0.83 % 0.00 %

N/A

USD 0.01B
AGED:LSE iShares Ageing Population.. 0.70 % 0.00 %

N/A

USD 0.46B
AGES:LSE iShares IV Public Limited.. 0.70 % 0.00 %

N/A

USD 0.46B
2B77:XETRA iShares Ageing Population.. 0.69 % 0.00 %

N/A

USD 0.50B
2B77:F iShares Ageing Population.. 0.69 % 0.00 %

N/A

N/A
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

N/A

USD 1.01B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

N/A

USD 0.25B
SCAP Series Portfolios Trust -.. 0.00 % 0.90 %

N/A

USD 3.04M
IBBJ 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 33.93% 81% B- 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 33.93% 81% B- 88% B+
Trailing 12 Months  
Capital Gain 41.51% 83% B 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 41.51% 83% B 88% B+
Trailing 5 Years  
Capital Gain 206.31% 90% A- 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 206.31% 90% A- 90% A-
Average Annual (5 Year Horizon)  
Capital Gain 30.38% 79% B- 85% B
Dividend Return 30.38% 79% B- 84% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 52.10% 54% F 32% F
Risk Adjusted Return 58.31% 96% N/A 84% B
Market Capitalization 1.64B 97% N/A 90% A-

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 21.10 28% 43%
Price/Book Ratio 58.55 3% 2%
Price / Cash Flow Ratio 16.66 4% 16%
Price/Free Cash Flow Ratio 13.43 3% 20%
Management Effectiveness  
Return on Equity 261.68% 100% 100%
Return on Invested Capital 16.62% 89% 85%
Return on Assets 13.48% 100% 97%
Debt to Equity Ratio 1,788.91% 1% 0%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.